The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2021 | Impact of prior systemic therapy on PFS patients enrolled in FIGHT-202
Ghassan K. Abou-Alfa, MD, MBA, Memorial Sloan Kettering Cancer Center, New York, NY, presents the findings of a post-hoc analysis of prior systemic therapy response on progression-free survival (PFS) patients enrolled in FIGHT-202 (NCT02924376), a Phase II study evaluating the efficacy and safety of pemigatinib in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma who have failed previous therapy. This interview took place at the ESMO World Congress on Gastrointestinal Cancer 2021.
